Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).
暂无分享，去创建一个
S. Culine | M. Climent | T. Choueiri | D. Bajorin | C. Sternberg | J. Bellmunt | D. Petrylak | D. Quinn | N. Vogelzang | D. Vaughn | L. Fong | A. Necchi | M. Puhlmann | W. Gerritsen | Y. Fradet | Jae-Lyun Lee | H. Gurney | Yabing Mai | R. Perini | R. Wit